Zobrazeno 1 - 10 of 16 pro vyhledávání: '"Susan M. Galbraith"'
1
Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging
Autor: Martin A. Lodge, Gordon J. S. Rustin, J. James Stirling, Luiza Sena, N. Jane Taylor, Gillian M. Tozer, Anwar R. Padhani, John Wilson, Ross J. Maxwell, Susan M. Galbraith
Publikováno v: Journal of Clinical Oncology. 21:2831-2842
Purpose: Combretastatin A4 phosphate (CA4P) is a novel vascular targeting agent. Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) studies were performed to examine changes in parameters related to blood flow and vascular permeability in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::edbd454af925f0c62d65b43bccec313f
https://doi.org/10.1200/jco.2003.05.187
Zobrazit plný text záznamu
2
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
Autor: Lisa K. Folkes, Luiza Sena, Helen Anderson, Gordon J. S. Rustin, Susan M. Galbraith, Michael R.L. Stratford, Lindsey Gumbrell, Patricia M Price
Publikováno v: Journal of Clinical Oncology. 21:2815-2822
Purpose: A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors. Patients and Methods: The drug was delivered by a 10-minute weekly infusi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54ae7a292418c837e4f4428c9bd490e8
https://doi.org/10.1200/jco.2003.05.185
Zobrazit plný text záznamu
3
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
Autor: Michael R.L. Stratford, K Bellenger, Susan M. Galbraith, L Gumbrell, S Waller, Paul M. Loadman, G. J. S. Rustin, Gavin Halbert, L Folkes, C Bradley
Publikováno v: British Journal of Cancer
The purpose of this phase I, dose-escalation study was to determine the toxicity, maximum tolerated dose, pharmacokinetics, and pharmacodynamic end points of 5,6-dimethylxanthenone acetic acid (DMXAA). In all, 46 patients received a total of 247 infu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a8e2780436c2381fa3b0a3c24317c19
https://doi.org/10.1038/sj.bjc.6600885
Zobrazit plný text záznamu
4
Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Autor: Michael B. Jameson, Susan M. Galbraith, Paul Thompson, Martin A. Lodge, Anwar R. Padhani, David Hough, J. James Stirling, Lindsey Gumbrell, Gordon J. S. Rustin, N. Jane Taylor
Publikováno v: Journal of Clinical Oncology. 20:3826-3840
PURPOSE: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) causes vascular shutdown in preclinical models. Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies were performed in the phase I trials to examine changes related to blood fl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a85a7f9a763426e90c619224508880d7
https://doi.org/10.1200/jco.2002.09.144
Zobrazit plný text záznamu
5
Repeatability of F-18-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies
Autor: Linda M. Velasquez, Susan M. Galbraith, Georgia Kollia, Ronald Boellaard, Wendy Hayes, Otto S. Hoekstra, Adriaan A. Lammertsma
Publikováno v: Journal of Nuclear Medicine, 50(10), 1646-1654. Society of Nuclear Medicine Inc.
Velasquez, L M, Boellaard, R, Kollia, G, Hayes, W, Hoekstra, O S, Lammertsma, A A & Galbraith, S M 2009, ' Repeatability of F-18-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies ', Journal of Nuclear Medicine, vol. 50, no. 10, pp. 1646-1654 . https://doi.org/10.2967/jnumed.109.063347
18F-FDG PET is often used to monitor tumor response in multicenter oncology clinical trials. This study assessed the repeatability of several semiquantitative standardized uptake values (mean SUV [SUVmean], maximum SUV [SUVmax], peak SUV [SUVpeak], a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aee5def04d8a40d0c951f4db9372ca08
https://research.vumc.nl/en/publications/9af27072-3d18-4f72-942f-44f771704c60
Zobrazit plný text záznamu
6
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer
Autor: Antoni Llombart-Cussac, Günther G. Steger, Hyerim Lee, Eva Ciruelos, Susan M. Galbraith, Sergei Tjulandin, Milvia Zambetti, A. Makhson, Suzanne Egyhazi, Kim E. Zerba, Georgy M. Manikhas, Edwin A. Clark, Mark Verrill, José Baselga, Ernst Kubista, Li-An Xu, Heinz Ludwig
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4)
Purpose This phase II study evaluated the efficacy and safety of ixabepilone as neoadjuvant therapy for invasive breast cancer not amenable to breast conservation surgery. Gene expression studies were undertaken using genes that were identified as po
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9825ed253afcc7cd2c80c19e2cf3db2
https://pubmed.ncbi.nlm.nih.gov/19075286
Zobrazit plný text záznamu
8
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature
Autor: Peter D, Davis, Graeme J, Dougherty, David C, Blakey, Susan M, Galbraith, Gillian M, Tozer, Angela L, Holder, Matthew A, Naylor, John, Nolan, Michael R L, Stratford, David J, Chaplin, Sally A, Hill
Publikováno v: Cancer research. 62(24)
Physiological differences between tumor and normal vasculature provide a target for drug discovery. In particular, the immature nature of tumor vasculature may render it intrinsically sensitive to disruption by agents affecting the endothelial cell c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e34afc198074e882562c177065bf2d7a
https://pubmed.ncbi.nlm.nih.gov/12499266
Zobrazit plný text záznamu
9
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis
Autor: Anwar R. Padhani, Martin A. Lodge, Susan M. Galbraith, J. James Stirling, N. Jane Taylor, Gordon J. S. Rustin, Søren M. Bentzen
Publikováno v: NMR in biomedicine. 15(2)
The purpose of this study was to determine the reproducibility of dynamic contrast-enhanced (DCE)-MRI and compare quantitative kinetic parameters with semi-quantitative methods, and whole region-of-interest (ROI) with pixel analysis. Twenty-one patie
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0240dea1dbec0e9cca1eab11d823b360
https://pubmed.ncbi.nlm.nih.gov/11870909
Zobrazit plný text záznamu
10
Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone
Autor: Li-An Xu, Susan M. Galbraith, Antonio Llombart, Günther G. Steger, J. Baselga, B. Paul, Hyerim Lee, Emma Clark, Shujian Wu
Publikováno v: Journal of Clinical Oncology. 24:3011-3011
3011 Background: Ixabepilone is a microtubule stabilizing agent with significant therapeutic value in breast cancer (BC) patients. To identify predictive biomarkers capable of identifying patients likely to receive optimal benefit from ixabepilone tr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0461d1808e7ca2f050e6591a87aed4c6
https://doi.org/10.1200/jco.2006.24.18_suppl.3011
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje